Where To Buy Peptides  ·  Vesugen · Safety

Vesugen side effects

Vesugen: the side effect lists you find online are not summaries of data. They are summaries of silence. No human trial of this peptide has collected an adverse event, because no randomized human trial exists.

WTBP Research Team Updated 2026-11-14 8 min read 5 cited sources

Search vesugen side effects and you get tidy lists. None of them trace to a human study. Randomized human trials of this peptide number zero, so no trial has ever recorded a side effect for it.

The short answer. Randomized human trials of Vesugen number zero, so no side effect data exists.

Vesugen is a 3-amino-acid peptide, Lys-Glu-Asp. Randomized human trials number zero. So no side effect table exists anywhere. The published rat work counted blood vessels, not harms. We found no published toxicology study for KED. “No reported side effects” means nobody has looked.

Does Vesugen have side effects?

Nobody can answer that from data. The honest answer is that the safety record is empty, not clean.

Vesugen is a synthetic 3-amino-acid peptide, Lys-Glu-Asp, often written KED. Its molecular weight is about 390 g/mol. Randomized human trials number zero. Adverse events are collected inside trials. No trial means no collection.

That matters more than it sounds. A side effect list for an approved drug is a count: how many people in each arm reported nausea, headache, injection site pain. For Vesugen there is no arm, no count and no denominator.

“No reported side effects” and “no side effects” are different sentences. The first describes a literature. The second describes a molecule. Only the first one is true here, and it is true because the studies that would generate reports were never run.

The wider picture is on the Vesugen complete guide, which sets out what the compound is and where it came from.

What the published studies actually measured

There is a literature. It is small, and its outcome measures are not safety measures.

2 related papers counted blood vessels in rat brain cortex. The titles tell you the endpoint.

Effects of vascular peptide bioregulator on the density of microvascular network in the brain cortex of aged rats.

Sokolova, Ryzhak, Mel’nikova, Sergeev & Khavinson, Bulletin of Experimental Biology and Medicine, 2016 — paper title

A 2018 paper in Advances in Gerontology ran the same kind of work in spontaneously hypertensive rats, looking at microcirculation in the cortex. A 2015 paper from the same group looked at endothelial cell proliferation in culture. A 2021 follow-up in Bulletin of Experimental Biology and Medicine looked at KED and genes tied to neurogenesis in Alzheimer’s disease.

Count the endpoints. Vessel density. Microcirculation. Cell proliferation. Gene expression. Not one of them is an adverse event.

What the rat work did show is covered in the Vesugen before and after page.

Why people say Vesugen has no side effects

The claim is usually built from chemistry, not from testing. The argument runs: the molecule is tiny, it is made of three ordinary amino acids, and the amounts used are small. Therefore it cannot hurt you.

That is a hypothesis. It is the same reasoning that was applied to the whole peptide bioregulator family, which has been under study by one Saint Petersburg group since the 1970s — roughly 50 years of work across 6+ peptides. The 2009 review that summarized that program is a review of the program by the people running it.

Peptide bioregulation of aging: results and prospects.

Anisimov & Khavinson, Biogerontology, 2009 — paper title

Self-reported safety from a compound’s own developers is the weakest form of safety evidence there is. The concentration problem is real here: one Russian lab wrote about 10 of the 12 KED papers, with only 1 recent independent paper outside it. Nobody with an incentive to find harm has gone looking.

The benefit side of that same literature is unpacked on the Vesugen benefits page.

Sponsored

Vesugen

Batch-matched COAHPLC + mass specResearch use only

The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.

Shop Vesugen

The risks that come from the vial, not the molecule

This is the part the side effect lists skip, and it is the part that is actually documented.

A research vial is not a pharmacy product. Nothing about Vesugen’s pharmacology has to be dangerous for a handling or purity problem to be. Those risks exist regardless of what the peptide does.

For a compound with no human safety data, the product-quality questions are the only safety questions that have answers. They are documents, and you can open them.

Is Vesugen approved by the FDA?

No. Vesugen is not approved by the FDA or the EMA. Russia permits it. That difference is regulatory, not scientific, and it does not import a safety review that was never performed here.

Safety questionWhat exists
Randomized human trialsZero
Human adverse-event dataNone found
Published toxicologyNone found
Human pharmacokineticsNone found
Rodent papers on vessels2 related papers
FDA or EMA approvalNo

Legal status for research compounds varies by country and by use. Are peptides legal covers the framework.

What would make the safety answer real

A short, specific list. None of it exists yet, and saying so is the point.

First, published toxicology with the species, duration and administered amounts stated. Second, a human dose-finding study that collects adverse events on a schedule. Third, replication by a lab outside the originating group, since 10 of the 12 papers currently come from one place. Fourth, human pharmacokinetics, so there is some idea of exposure.

Until those appear, the correct description of Vesugen is a rodent and cell-culture tool with an unknown human safety profile. Not a safe compound. Not a dangerous one. An untested one.

Sponsored

Vesugen

Batch-matched COAHPLC + mass specResearch use only

Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.

Learn more

What to know now

What we're watching

Watch the gap between “no reported side effects” and “tested and found safe.” For Vesugen only the first is true, and it is true because no human study collected reports. The checkable risks are the ones attached to the vial: a current third-party certificate of analysis, sterile handling at reconstitution, and cold storage.

Frequently asked questions

Is Vesugen safe?

Unknown. Randomized human trials number zero, and we found no published toxicology study. Safety is a measurement, and this measurement has not been made. A compound with no safety data is untested, not safe.

Are there any reported side effects of Vesugen?

We found no published human adverse-event reports. That is because no human trial collected them, not because a study looked and found nothing. The rat papers measured vessel density and microcirculation in brain cortex, which are efficacy endpoints.

Does Vesugen affect blood pressure?

No study we found measured blood pressure in people. A 2018 paper in Advances in Gerontology used spontaneously hypertensive rats, but the reported outcome was microcirculation in the brain cortex. Human cardiovascular effects, helpful or harmful, are unmeasured.

Is Vesugen FDA approved?

No. It is not approved by the FDA or the EMA. Russia permits it. Approval elsewhere is a regulatory fact and does not mean a US-style safety review was performed.

What is the biggest practical risk with a Vesugen vial?

Product quality, not known pharmacology. Identity, sterility and degradation are the risks that can actually be checked. A third-party certificate of analysis, clean reconstitution and correct storage temperature are the documents and steps that address them.

Why do vendor pages say it is well tolerated?

That phrasing comes from the developing group's own summaries of a peptide program running since the 1970s. Self-reported tolerability from a compound's originators is the weakest form of safety evidence, and here it is not backed by a published human trial.

References

  1. Anisimov, V. N., & Khavinson, V. K. (2009). Peptide bioregulation of aging: Results and prospects. Biogerontology, 11(2), 139–149. https://doi.org/10.1007/s10522-009-9249-8
  2. Sokolova, I. B., Ryzhak, G. A., Mel’nikova, E. V., Sergeev, I. V., & Khavinson, V. K. (2016). Effects of vascular peptide bioregulator on the density of microvascular network in the brain cortex of aged rats. Bulletin of Experimental Biology and Medicine, 161(4), 569–572. https://doi.org/10.1007/s10517-016-3400-8
  3. Sokolova, I. B., Ryzhak, G. A., & Khavinson, V. K. (2018). Functional cumulation of the influence of vascular peptide bioregulator on microcirculation in the brain cortex of spontaneously hypertensive rats. Advances in Gerontology, 8(2), 119–123. https://doi.org/10.1134/s2079057018020170
  4. Khavinson, V. K., Tarnovskaya, S. I., Linkova, N. S., Gutop, E. O., & Elashkina, E. V. (2015). Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation in aging. Advances in Gerontology, 5(4), 217–220. https://doi.org/10.1134/s2079057015040116
  5. Khavinson, V. K., Lin’kova, N. S., & Umnov, R. S. (2021). Peptide KED: Molecular-genetic aspects of neurogenesis regulation in Alzheimer’s disease. Bulletin of Experimental Biology and Medicine, 171(2), 190–193. https://doi.org/10.1007/s10517-021-05192-6

every peptide, every supplier question, one library.